About the new and improved Hot Tort Report
Being industry experts, we pride ourselves on keeping our finger on the pulse of all things Multi District Litigation. This predominantly consists of providing our subscribers with competitive insights into where the money is being spent in hopes of informing your blueprint for advertising strategies. These cases can be highly lucrative, but are difficult to acquire, requiring significant investment and patience to secure high-value cases.
We’ve been working hard on an algorithm to deliver more than just monthly TV spends and are proud to announce that we are ready to unveil our HTR 2.0.
This new list offers an overview of dollars spent across TV, Meta, PPC, and more, assigning a score to each tort based on what we, as leaders in the law firm advertising space, are witnessing across these various platforms.
The Hot Tort Report:
June 2026
The Hottest in Mass Tort Spending: May 2026
Social Media Addiction
Featured Tort
Subscribe to the Hot Tort Report
What’s the Tort News?
Published: June, 2026. Advertising spend from multiple sources for a recent 30 day period.
If you have any questions, please contact us at national@whitehardt.com
#1 Social Media Addiction
Social Media Addiction reclaimed the #1 spot this month after last month’s leader, Roundup®, cooled from its TV-driven surge. The shift came as Social Media Addiction added TV activity, while Meta remained maxed out and PPC stayed strong.
The litigation pressure also continued to build in May. The U.S. Supreme Court declined to hear Meta’s appeal in the Vermont case, allowing the state’s lawsuit to move forward. Meta also settled with Breathitt County School District in a case selected as a test case for more than 1,000 similar school district lawsuits. Needless to say, this tort is back on top.
For metrics such as CPA, CPL, or common criteria, please contact us.
#2 Diabetes Meds for Weight Loss
Diabetes Meds for Weight Loss moved into the #2 position this month, supported by a maxed-out WHii score and continued strength on Meta. Recent filings continue to expand the injury profile beyond gastrointestinal claims. A newly filed Ozempic® complaint in the GLP-1 RA NAION MDL alleges that the plaintiff developed non-arteritic anterior ischemic optic neuropathy (NAION), an irreversible condition that can cause sudden and permanent vision loss, after using Ozempic®. The complaint also alleges that no version of the Ozempic® label has warned patients or doctors that taking the drug may cause NAION or result in permanent vision loss.
Even with a lighter TV score this month, the tort remains backed by broad digital activity and an expanding legal footprint.
CPA: $91 – $751
CPL: $68 – $563
Common Criteria: Took a prescription diabetes drug for weight loss (e.g. Ozempic®, Mounjaro®), discontinued use of the drug, and experienced one or more gastrointestinal disorders at least 30 days after your first dose.
#3 Roundup®
Roundup® fell from the top spot this month as TV activity pulled back from April’s surge. The campaign is no longer getting the same broadcast push that drove last month’s jump, but advertiser interest has not left the field.
The litigation remains highly active on 2 fronts. Bayer’s proposed $7.25 billion settlement is facing pushback from claimants and attorneys who argue the deal is inadequate and could limit the rights of people with Roundup®-related cancer claims. At the same time, the U.S. Supreme Court is weighing whether federal labeling rules block state-level failure-to-warn lawsuits, a decision that could reshape thousands of pending claims.
Roundup® is still playing in high-pressure territory even after cooling from last month’s TV-driven run.
CPA: $1,238
CPL: $743
For common criteria, please contact us.
#4 Birth Control Injections
Birth Control Injections moved up to #4 this month, with gains in both WHii and TV giving the campaign more lift.
Plaintiffs’ leadership reported that expert discovery for preemption and general causation is complete, Daubert briefing is underway, and the general causation hearing is scheduled for June 24 and 25. The first pilot trial remains set for December 7, 2026, keeping the litigation on a defined track as discovery continues.
With more than 5,500 cases in the MDL and both litigation visibility and TV activity rising this month, Birth Control Injections is gaining ground again after holding steady in the middle of the pack.
CPA: $5,169
CPL: $3,050
For common criteria, please contact us.
#5 Roblox Child Abuse
TV activity dropped out for this tort completely, but the Roblox Child Abuse campaign still gained ground because digital performance and visibility strengthened.
This is a notable shift from April, when Roblox held onto a top 10 spot despite broader cooling. May’s numbers show the campaign regaining momentum without relying on broadcast activity, putting it back in the upper half of the field.
For metrics such as CPA, CPL, and common criteria, please contact us.
#6 Rideshare Assault
The rise in WHii for the Rideshare Assault mass tort reflects continued movement in the broader litigation. Uber sexual assault claims now include more than 3,000 federal MDL cases and more than 800 California state court cases, with the next bellwether trial scheduled for September 2026. Recent Lyft filings also keep the rideshare category active beyond Uber alone.
The score improved, but in a competitive month, steady digital strength was not enough to move this tort higher on the board.
For metrics such as CPA, CPL, and common criteria, please contact us.
#7 Paraquat
Paraquat moved up one position this month, supported by gains in WHii and Meta. The WHii increase lines up with renewed public and regulatory attention after Vermont became the first U.S. state to ban paraquat over concerns tied to Parkinson’s disease. With Meta still carrying most of the campaign and WHii moving higher, Paraquat gained enough ground to climb in a crowded middle tier.
CPA: $711
CPL: $320
Common Criteria: Diagnosis of Parkinson’s Disease or experiencing Parkinson’s-like symptoms after exposure to Paraquat.
#8 Talcum Powder
Talcum Powder dropped 4 positions this month as both WHii and PPC pulled back. Meta remained maxed out, but with TV still inactive and less support from PPC, the campaign lost ground while other torts gained more momentum around it.
Even with the ranking drop, Talcum Powder remains in the top 10 thanks to continued digital strength and ongoing visibility.
CPA: $940
CPL: $470
For common criteria, please contact us.
#9 Birth Injury
Birth Injury returned to the Hot Tort Report this month with Meta activity maxed out and WHii providing enough activity to bring it back into the top 10. This is another digital-led entry in a report where broadcast activity is concentrated higher up the rankings.
A recent $108.6 million Philadelphia birth injury verdict against Jefferson Health added to the visibility around this category. The award follows other major medical malpractice verdicts in the same market, reinforcing how high the stakes can be in birth injury claims.
With Meta carrying the campaign and WHii back in play, Birth Injury earned its way onto the board again after several months outside the rankings.
For metrics such as CPA, CPL, and common criteria, please contact us.
#10 Takata Airbag Recall
Takata Airbag Recall is back in the top 10, driven almost entirely by TV activity. With TV maxed out and only limited support from WHii, Meta, and PPC, this is the most broadcast-dependent campaign on the board.
The recall continues to resurface despite its age. A recent Stellantis Do Not Drive warning added around 225,000 older vehicles to the ongoing Takata-related activity, reminding consumers that unresolved recall issues are still creating safety concerns years after the first wave of cases.
For metrics such as CPA, CPL, and common criteria, please contact us.
Mesothelioma
You may be noticing a tort missing from our new report. While Mesothelioma continues to dominate the competition when it comes to spend levels, Whitehardt finds that this tort is its own niche animal. These cases can be extremely fruitful, but hard to come by, requiring a high buy-in to get in the game and patience when landing that ringer of a case. We believe that Meso will remain a constant for some time, but in regards to many of the other drugs and devices we focus on in this monthly report, we’ve decided to move it to its own category. If you are interested in hearing the latest news on Meso or how Whitehardt may be currently seeking these cases, you can contact us here.
Whitehardt will continue to track meso spending from month to month, so if you are interested in ongoing meso spending, please reach out to us directly. Going forward, we will be excluding meso from these tort reports.